A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Biib059 In Participants With Active Subacute Cutaneous Lupus Erythematosus And/Or Chronic Cutaneous
Posted Date: Nov 5, 2024
- Investigator: Debra Breneman
- Specialties:
- Type of Study: Drug
The purpose of this study is to evaluate the efficacy and safety of BIIB059 (litifilimab) compared to placebo in participants with active SCLE and/or CCLE with or without systemic manifestations and refractory and/or intolerant to antimalarials.
Criteria:
Null
Keywords:
Cutaneous Lupus Erythematosus, Lupus
For More Information:
Jordan Sambrookes
NULL
perryj8@ucmail.uc.edu